New Releases from NCBI BookshelfZolbetuximab for Injection (Vyloy): Indication: In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumours are Claudin 18.2 positive: Reimbursement Recommendation [Internet].​Zolbetuximab for Injection (Vyloy): Indication: In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumours are Claudin 18.2 positive: Reimbursement Recommendation [Internet].